Dasatinib Stada 100 mg film-coated tablets – patient leaflet, side effects, dosage

1. What Dasatinib film-coated tablets are and what they are used for

Dasatinib film-coated tablets contain the active substance dasatinib. This medicine is used to treat chronic myeloid leukaemia (CML) in adults, adolescents and children at least 1 year of age. Leukaemia is a cancer of white blood cells. These white cells usually help the body to fight infection. In people with CML, white cells called granulocytes start growing out of control. Dasatinib inhibits the growth of these leukaemic cells.

Dasatinib film-coated tablets are also used to treat Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) in adults, adolescents and children at least 1 year of age, and lymphoid blast CML in adults who are not benefiting from prior therapies. In people with ALL, white cells called lymphocytes multiply too quickly and live too long. Dasatinib inhibits the growth of these leukaemic cells. If you have any questions about how Dasatinib film-coated tablets work or why this medicine has been prescribed for you, ask your doctor.

2. What you need to know before you take Dasatinib film-coated tablets

Do not take Dasatinib film-coated tablets

• if you are allergic to dasatinib or any of the other ingredients of this medicine (listed in section 6). If you could be allergic, ask your doctor for advice. Warnings and precautions

Talk to your doctor or pharmacist before using Dasatinib film-coated tablets

• if you are taking medicines to thin the blood or prevent clots (see “Other medicines and Dasatinib film-coated tablets”)
• if you have a liver or heart problem, or used to have one
• if you start having difficulty breathing, chest pain, or a cough when taking dasatinib: this may be a sign of fluid retention in the lungs or chest (which can be more common in patients aged 65 years and older), or due to changes in the blood vessels supplying the lungs
• if you experience bruising, bleeding, fever, fatigue and confusion when taking dasatinib, contact your doctor. This may be a sign of damage to blood vessels known as thrombotic microangiopathy (TMA).

Your doctor will regularly monitor your condition to check whether dasatinib is having the desired effect. You will also have blood tests regularly while you are taking Dasatinib film-coated tablets.

Children and adolescents

Do not give this medicine to children younger than 1 year of age. There is limited experience with the use of dasatinib in this age group. Bone growth and development will be closely monitored in children taking this medicine.

Other medicines and Dasatinib film-coated tablets Tell your doctor if you are taking, have recently taken or might take any other medicines.

Dasatinib is mainly handled by the liver. Certain medicines may interfere with the effect of dasatinib when taken together.

These medicines are not to be used with Dasatinib:

• ketoconazole, itraconazole - these are antifungal medicines
• erythromycin, clarithromycin, telithromycin - these are antibiotics
• ritonavir - this is an antiviral medicine • phenytoin, carbamazepine, phenobarbital - these are treatments for epilepsy
• rifampicin - this is a treatment for tuberculosis • famotidine, omeprazole - these are medicines that block stomach acids
• St. John’s wort - a herbal preparation obtained without a prescription, used to treat depression and other conditions (also known as Hypericum perforatum)

Do not take medicines that neutralise stomach acids (antacids such as aluminium hydroxide or magnesium hydroxide) in the 2 hours before or 2 hours after taking dasatinib.

Tell your doctor if you are taking medicines to thin the blood or prevent clots.

Dasatinib film-coated tablets with food and drink

Do not take dasatinib with grapefruit or grapefruit juice.

Pregnancy and breast-feeding

If you are pregnant or think you may be pregnant, tell your doctor immediately. Dasatinib is not to be used during pregnancy unless clearly necessary. Your doctor will discuss with you the

potential risk of taking dasatinib during pregnancy. Both men and women taking dasatinib will be advised to use effective contraception during treatment. If you are breast-feeding, tell your doctor. You should stop breast-feeding while you are taking dasatinib.

Driving and using machines

Take special care when driving or using machines in case you experience side effects such as dizziness and blurred vision.

Dasatinib film-coated tablets contain lactose

If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.

Dasatinib film-coated tablets contain sodium

This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’.

3. How to take Dasatinib film-coated tablets

Dasatinib film-coated tablets will only be prescribed to you by a doctor with experience in treating leukaemia. Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. Dasatinib film-coated tablets are prescribed for adults, adolescents and children at least 1 year.

The starting dose recommended for adult patients with chronic phase CML is 100 mg once a day. The starting dose recommended for adult patients with Ph+ ALL is 140 mg once a day.

Dosing for children with chronic phase CML or Ph+ ALL is on the basis of body weight.

Dasatinib is administered orally once daily in the form of either tablets or powder for oral suspension. Dasatinib film-coated tablets are not recommended for patients weighing less than 10 kg. The powder for oral suspension should be used for patients weighing less than 10 kg and patients who cannot swallow tablets. A change in dose may occur when switching between formulations (i.e., tablets and powder for oral suspension), so you should not switch from one to the other.

Your doctor will decide the right formulation and dose based on your weight, any side effects and response to treatment. The starting dose of dasatinib for children is calculated by body weight as shown below:

Body Weight (kg) ^a Daily Dose (mg)

10 to less than 20 kg 40 mg

20 to less than 30 kg 60 mg

30 to less than 45 kg 70 mg

at least 45 kg 100 mg

^a The tablet is not recommended for patients weighing less than 10 kg; the powder for oral suspension should be used for these patients.

There is no dose recommendation for Dasatinib film-coated tablets with children under 1 year of age. Depending on how you respond to the treatment, your doctor may suggest a higher or lower dose, or even stopping treatment briefly. For higher or lower doses, you may need to take combinations of the different tablet strengths.

How to take Dasatinib film-coated tablets

Take your tablets at the same time every day. Swallow the tablets whole. Do not crush, cut or chew them. Do not take dispersed tablets. You cannot be sure you will receive the correct dose if you crush, cut, chew or disperse the tablets. They can be taken with or without a meal.

Special handling instructions for Dasatinib film-coated tablets

It is unlikely that the Dasatinib film-coated tablets will get broken. But if they do, persons other than the patient should use gloves when handling Dasatinib film-coated tablets.

How long to take Dasatinib film-coated tablets

Take Dasatinib film-coated tablets daily until your doctor tells you to stop. Make sure you take Dasatinib film-coated tablets for as long as it is prescribed. If you take more Dasatinib film-coated tablets than you should

If you have accidentally taken too many tablets, talk to your doctor immediately. You may require medical attention.

If you forget to take Dasatinib film-coated tablets

Do not take a double dose to make up for a forgotten tablet. Take the next scheduled dose at the regular time. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. The following can all be signs of serious side effects:

• if you have chest pain, difficulty breathing, coughing and fainting
• if you experience unexpected bleeding or bruising without having an injury
• if you find blood in your vomit, stools or urine, or have black stools
• if you get signs of infections such as fever, severe chills
• if you get fever, sore mouth or throat, blistering or peeling of your skin and/or mucous membranes Contact your doctor immediately if you notice any of the above.

Very common side effects (may affect more than 1 in 10 people)

• Infections (including bacterial, viral and fungal)

• Heart and lungs: shortness of breath

  9287209 2503 GB P18-0785R/18B

006467

• Digestive problems: diarrhoea, feeling or being sick (nausea, vomiting)
• Skin, hair, eye, general: skin rash, fever, swelling around the face, hands and feet, headache, feeling tired or weak, bleeding
• Pain: pain in the muscles (during or after discontinuing treatment), tummy (abdominal) pain
• Tests may show: low blood platelet count, low white blood cells count (neutropenia), anaemia, fluid around the lungs

Common side effects (may affect up to 1 in 10 people)

• Infections: pneumonia, herpes virus infection (including cytomegalovirus-CMV), upper respiratory tract infection, serious infection of the blood or tissues (including uncommon cases with fatal outcomes)
• Heart and lungs: palpitations, irregular heartbeat, congestive heart failure, weak heart muscle, high blood pressure, increased blood pressure in the lungs, cough
• Digestive problems: appetite disturbances, taste disturbance, bloated or distended tummy (abdomen), inflammation of the colon, constipation, heartburn, mouth ulceration, weight increase, weight decrease, gastritis
• Skin, hair, eye, general: skin tingling, itching, dry skin, acne, inflammation of the skin, persistent noise in ears, hair loss, excessive perspiration, visual disorder (including blurred vision and disturbed vision), dry eye, bruise, depression, insomnia, flushing, dizziness, contusion (bruising), anorexia, somnolence, generalised oedema
• Pain: pain in joints, muscular weakness, chest pain, pain around hands and feet, chills, stiffness in muscles and joints, muscle spasm
• Tests may show: fluid around the heart, fluid in the lungs, arrhythmia, febrile neutropenia, gastrointestinal bleeding, high uric acid levels in the blood

Uncommon side effects (may affect up to 1 in 100 people)

• Heart and lungs: heart attack (including fatal outcome), inflammation of the lining (fibrous sack) surrounding the heart, irregular heartbeat, chest pain due to lack of blood supply to the heart (angina), low blood pressure, narrowing of airway that may cause breathing difficulties, asthma, increased blood pressure in the arteries (blood vessels) of the lungs
• Digestive problems: inflammation of the pancreas, peptic ulcer, inflammation of the food pipe, swollen tummy (abdomen), tear in the skin of the anal canal, difficulty in swallowing, inflammation of the gallbladder, blockage of bile ducts, gastro-oesophageal reflux (a condition where acid and other stomach contents come back up into the throat)
• Skin, hair, eye, general: allergic reaction including tender, red lumps on the skin (erythema nodosum), anxiety, confusion, mood swings, lower sexual drive, fainting, tremor, inflammation of the eye which causes redness or pain, a skin disease characterised by tender, red, well-defined blotches with the sudden onset of fever and raised white blood cell count (neutrophilic dermatosis), loss of hearing, sensitivity to light, visual impairment, increased eye tearing, disturbance in skin colour, inflammation of fatty tissue under the skin, skin ulcer, blistering of the skin, nail disorder, hair disorder, hand-foot disorder, renal failure, urinary frequency, breast enlargement in men, menstrual disorder, general weakness and discomfort, low thyroid function, losing balance while walking, osteonecrosis (a disease of reduced blood flow to the bones, which can cause bone loss and bone death), arthritis, skin swelling anywhere in the body
• Pain: inflammation of vein which can cause redness, tenderness and swelling, inflammation of the tendon
• Brain: loss of memory
• Tests may show: abnormal blood test results and possibly impaired kidney function caused by the waste products of the dying tumour (tumour lysis syndrome), low levels of albumin in the blood, low levels of lymphocytes (a type of white blood cell) in the blood, high level of cholesterol in the blood, swollen lymph nodes, bleeding in the brain, irregularity of the electrical activity of the heart, enlarged heart, inflammation of the liver, protein in the urine, raised creatine phosphokinase (an enzyme mainly found in the heart, brain and skeletal muscles), raised troponin (an enzyme mainly found in the heart and skeletal muscles), raised gamma-glutamyltransferase (an enzyme mainly found in the liver), milky-appearing fluid around the lungs (chylothorax)

Rare side effects (may affect up to 1 in 1,000 people)

• Heart and lungs: enlargement of the right ventricle in the heart, inflammation of the heart muscle, collection of conditions resulting from blockage of blood supply to the heart muscle (acute coronary syndrome), cardiac arrest (stopping of blood flow from the heart), coronary (heart) artery disease, inflammation of the tissue covering the heart and lungs, blood clots, blood clots in the lungs
• Digestive problems: loss of vital nutrients such as protein from your digestive tract, bowel obstruction, anal fistula (an abnormal opening from the anus to the skin around the anus), impairment of kidney function, diabetes
• Skin, hair, eye, general: convulsion, inflammation of the optic nerve that may cause a complete or partial loss of vision, blue-purple mottling of the skin, abnormally high thyroid function, inflammation of the thyroid gland, ataxia (a condition associated with lack of muscular coordination), difficulty walking, miscarriage, inflammation of the skin blood vessels, skin fibrosis
• Brain: stroke, temporary episode of neurologic dysfunction caused by loss of blood flow, facial nerve paralysis, dementia
• Immune system: severe allergic reaction

• Musculoskeletal and connective tissue: delayed fusion of the rounded ends that form joints (epiphyses); slower or delayed growth

  Other side effects that have been reported with frequency not known (frequency cannot be estimated from the available data):

  • Inflammation of the lungs
  • Bleeding in the stomach or bowels that can cause death
  • Recurrence (reactivation) of hepatitis B infection when you have had hepatitis B in the past (a liver infection)
  • A reaction with fever, blisters on the skin, and ulceration of the mucous membranes
  • Disease of the kidneys with symptoms including oedema and abnormal laboratory test results such as protein in the urine and low protein level in the blood
  • Damage to blood vessels known as thrombotic microangiopathy (TMA), including decreased red blood cell count, decreased platelets, and formation of blood clots

Your doctor will check for some of these effects during your treatment.

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for ‘MHRA Yellow Card’in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Dasatinib film-coated tablets

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the bottle label, blister or carton after EXP. The expiry date refers to the last day of that month. This medicine does not require any special storage conditions.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information What Dasatinib film-coated tablets contain

• The active substance is dasatinib. Each film-coated tablet contains 20 mg, 50 mg, 80 mg, 100 mg or 140 mg dasatinib.
• The other ingredients are:

Tablet core: cellulose, microcrystalline (E460), lactose monohydrate (see section 2 “What you need to know before you take Dasatinib film-coated tablets”); croscarmellose sodium, hydroxypropylcellulose (E463), magnesium stearate (E470b)

Film-coating: poly(Vinyl Alcohol) (E1203), titanium dioxide (E171), talc (E553b), glyceryl monostearate (E471), sodium laurilsulfate.

What Dasatinib film-coated tablets look like and contents of the pack

Dasatinib 20 mg film-coated tablets

The film-coated tablet is white to off-white, biconvex, round with “20” debossed on one side and “and plain on the other, with a diameter of 6.1 mm.

Dasatinib 50 mg film-coated tablets

The film-coated tablet is white to off-white, biconvex, oval with “50” debossed on one side and plain on the other, with dimensions 10.9 mm x 5.8 mm. Dasatinib 80 mg film-coated tablets

The film-coated tablet is white to off-white, biconvex, triangular with “80” debossed on one side and plain on the other, with dimensions 10.3 mm x 10.0 mm. Dasatinib 100 mg film-coated tablets

The film-coated tablet is white to off-white, biconvex, oval with “100” debossed on one side plain on the other, with dimensions 14.8 mm x 7.2 mm. Dasatinib 140 mg film-coated tablets

The film-coated tablet is white to off-white, biconvex, round with “140” debossed on one side and plain on the other, with a diameter of 11.8 mm.

Dasatinib 20 mg and 50 mg film-coated tablets Aluminium-OPA/Alu/PVC blisters (perforated unit dose blisters).

Aluminium-OPA/Alu/PVC blisters.

High density polyethylene (HDPE) bottle with a polypropylene child-resistant closure and a plastic (HDPE) canister containing silica gel.

Carton containing 60 x 1 or 100 x 1 film-coated tablets in perforated unit dose blisters.

Carton containing 60 or 100 film-coated tablets in blisters.

Carton containing one bottle with 60 film-coated tablets.

Dasatinib 80 mg, 100 mg and, 140 mg film-coated tablets

Aluminium-OPA/Alu/PVC blisters (perforated unit dose blisters).

Aluminium-OPA/Alu/PVC blisters.

High density polyethylene (HDPE) bottle with a polypropylene child-resistant closure and a plastic (HDPE) canister containing silica gel.

Carton containing 30 x 1, 60 x 1 or 100 x 1 film-coated tablets in perforated unit dose blisters.

Carton containing 30, 60 or 100 film-coated tablets in blisters.

Carton containing one bottle with 30 film-coated tablets.

Not all pack sizes may be marketed.

Marketing Authorisation Holder

STADA, Linthwaite, Huddersfield, HD7 5QH, UK Manufacturer

Remedica Ltd., Aharnon Street, Limassol Industrial Estate, 3056 Limassol, Cyprus

This leaflet was last revised in February 2025

9287209 2503 GB

P18-0785R/18B ⁰⁰⁶⁴⁶⁷ MOC Number:

STADA Mat.-Nr./Mat.-No.:

Hersteller/Manufacturer:

Hersteller Art.-Nr./Manufacturer Art.-No.:

Format/Size:

Genehmigt/Approved

Version: 2 Datum/Date:

Grafik erstellt von/Graphic made by: Agentur/Agency:

Flattermarke/Collating mark:

PZN/EAN:

1. 1. Farbe/Colour:
2. 2. Farbe/Colour:
3. 3. Farbe/Colour:
4. 4. Farbe/Colour:
5. 5. Farbe/Colour:
6. 6. Farbe/Colour:
7. 7. Farbe/Colour:
8. 8. Farbe/Colour:
9. 9. Farbe/Colour:
10. 10. Farbe/Colour:
11. 11. Farbe/Colour:
12. 12. Farbe/Colour:
13. 13. Farbe/Colour:
14. 14. Farbe/Colour:
15. 15. Farbe/Colour:
16. 16. Farbe/Colour:

NTIN/GTIN:

Aktueller Umlauf/Current loop:

Schriftgröße/Font-size:

Produkt/Product: DASATINIB FTA SD GB:PIL

9287209_2503_GB

STADA Art.-Nr./Art.-No:

162895/162894/162893/162892/

162890

P18-0785R/18B

157 x 500 mm

N/A

N/A

006467

N/A Black

24.03.2025 MOC-2025-0688 A